[go: up one dir, main page]

RU93049153A - Лечение жирными кислотами - Google Patents

Лечение жирными кислотами

Info

Publication number
RU93049153A
RU93049153A RU93049153/14A RU93049153A RU93049153A RU 93049153 A RU93049153 A RU 93049153A RU 93049153/14 A RU93049153/14 A RU 93049153/14A RU 93049153 A RU93049153 A RU 93049153A RU 93049153 A RU93049153 A RU 93049153A
Authority
RU
Russia
Prior art keywords
fatty acids
treatment
linolenic
gamma
acid
Prior art date
Application number
RU93049153/14A
Other languages
English (en)
Other versions
RU2122409C1 (ru
Inventor
Фредерик Хорробин Дэвид
Элизабет Рейнольдс Бренда
Original Assignee
Скотиа Холдингс ПЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929217780A external-priority patent/GB9217780D0/en
Application filed by Скотиа Холдингс ПЛС filed Critical Скотиа Холдингс ПЛС
Publication of RU93049153A publication Critical patent/RU93049153A/ru
Application granted granted Critical
Publication of RU2122409C1 publication Critical patent/RU2122409C1/ru

Links

Claims (1)

  1. Способ повышения усвоения кальция в кишечнике человека и животных заключается в введении жирных кислот (гамма-линоленовой, лигомо-гамма-линоленовой или линоловой кислоты) или самих по себе, или в виде соли, или в другой фармацевтически приемлемой форме, возможно в сочетании с эйкозапентаеновой кислотой, докозогексаеновой кислотой или с другими эйкозановыми жирными кислотами в аналогичном виде. Способ, в частности полезен при лечении остеопороза.
RU93049153A 1992-08-21 1993-08-20 Лечение жирными кислотами RU2122409C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929217780A GB9217780D0 (en) 1992-08-21 1992-08-21 Fatty acid treatment
GB9217780.7 1992-08-21

Publications (2)

Publication Number Publication Date
RU93049153A true RU93049153A (ru) 1996-06-10
RU2122409C1 RU2122409C1 (ru) 1998-11-27

Family

ID=10720716

Family Applications (1)

Application Number Title Priority Date Filing Date
RU93049153A RU2122409C1 (ru) 1992-08-21 1993-08-20 Лечение жирными кислотами

Country Status (21)

Country Link
US (1) US5618558A (ru)
EP (1) EP0585026B1 (ru)
JP (1) JPH06157303A (ru)
KR (1) KR940003553A (ru)
CN (1) CN1049334C (ru)
AT (1) ATE159856T1 (ru)
AU (1) AU666747B2 (ru)
CA (1) CA2104567A1 (ru)
DE (1) DE69315020T2 (ru)
DK (1) DK0585026T3 (ru)
ES (1) ES2110060T3 (ru)
GB (1) GB9217780D0 (ru)
GR (1) GR3025898T3 (ru)
HK (1) HK1000997A1 (ru)
MY (1) MY109928A (ru)
NO (1) NO306655B1 (ru)
NZ (1) NZ248422A (ru)
RU (1) RU2122409C1 (ru)
SG (1) SG80536A1 (ru)
TW (1) TW323230B (ru)
ZA (1) ZA935976B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
US5804210A (en) * 1996-08-07 1998-09-08 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
WO1999003456A2 (en) * 1997-07-16 1999-01-28 Societe Des Produits Nestle S.A. Method for prophylaxis or treatment of bone density loss
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6479545B1 (en) * 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
EG22407A (en) 2000-02-17 2003-01-29 Iams Company Method for improving bone modeling and chondrocyte functioning in growing canines
EP1852115A1 (en) * 2001-03-15 2007-11-07 DSM IP Assets B.V. Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
CN1259044C (zh) * 2001-03-30 2006-06-14 日清奥利友集团株式会社 骨代谢改善剂
WO2005108535A2 (en) * 2004-04-30 2005-11-17 Nutriscience Technology, Inc. Polyunsaturated fatty acid monovalent and divalent metal salt synthesis
US7098352B2 (en) * 2001-11-16 2006-08-29 Virtus Nutrition Llc Calcium salt saponification of polyunsaturated oils
GB2409644B (en) * 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
EP1968402A2 (en) * 2005-10-07 2008-09-17 Ocean Nutrition Canada Limited Salts of fatty acids and methods of making and using thereof
DE102007022694A1 (de) * 2007-05-11 2008-11-13 Humana Milchunion Eg Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
DE102007039310A1 (de) * 2007-08-13 2009-02-19 Eberhard-Karls-Universität Tübingen Universitätsklinikum Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
ES2862336T3 (es) 2008-09-02 2021-10-07 Amarin Pharmaceuticals Ie Ltd Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
EP2596786B1 (en) 2009-02-10 2019-11-27 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
CN104856985B (zh) 2009-04-29 2019-01-04 阿马里纳制药爱尔兰有限公司 稳定的药物组合物和使用其的方法
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2011222544A1 (en) * 2010-03-04 2012-09-27 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
US8178707B2 (en) 2010-03-25 2012-05-15 Jost Chemical Company Co-precipitated salts of fatty acids
CN101978949A (zh) * 2010-11-16 2011-02-23 王京南 γ-亚麻酸酯脂肪乳静脉注射液及其制造方法
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
CN111840269A (zh) 2012-06-29 2020-10-30 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2953633A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017207124A1 (en) * 2016-06-01 2017-12-07 Nestec S.A. Composition for use in the prophylaxis of allergic disease
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750535A1 (en) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417119A (en) * 1972-11-30 1975-12-10 Thiele G H Process for treating bones
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
JPH0625057B2 (ja) * 1987-12-14 1994-04-06 日本油脂株式会社 骨形成促進剤
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment

Similar Documents

Publication Publication Date Title
RU93049153A (ru) Лечение жирными кислотами
DE69315020D1 (de) Verwendung von Fettsäuren zur Erhöhung der Calciumabsorption im Darm
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
GB2218984B (en) Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
HK1003775A1 (en) Fat mixture process for its preparation and its use
HK37694A (en) Fatty acids compositions
RU92016445A (ru) Применение амидов изоксазол-4-карбоновой кислоты и амидов гидроксиалкилиденциануксусной кислоты
ES2117390T3 (es) Sales de un acido graso poliinsaturado y formulaciones farmaceuticas que las contienen.
CA2159058A1 (en) Inhibition of helicobacter
ATE43242T1 (de) Pharmazeutische oder diaetetische zusammensetzung mit hoher antithrombotischer und antiarteriosklerotischer wirkung.
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
KR930000114A (ko) 지방산을 이용한 치료
ES2149253T3 (es) Medicamentos a base de acido docosahexaenoico como antiagregantes plaquetarios y contra las carencias cerebrales en acidos grasos esenciales y procedimientos de preparacion.
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
FI863976A0 (fi) Terapeutisk komposition.
ES2171535T3 (es) Producto nutritivo utilizado en el tratamiento de la colitis ulcerosa y su uso.
ATE135909T1 (de) Verfahren zur behandlung von akne
EP0302481A3 (en) Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
RU93049092A (ru) Лечение жирными кислотами
ES2082390T3 (es) Acido gamma-linolenico para la preparacion de un medicamento para impedir la reoclusion de las arterias.
MA20097A1 (fr) Procede de preparation du diniflumate d'ester morpholineotylique d'acide niflumique utilise en therapeutique comme analgesique et anti-inflammatoire.
KR890009868A (ko) 1-메틸-β-옥소-α-(페닐카바모일)-2- 피롤프로피오니트릴의 트로메트아민염
ATE79750T1 (de) Pharmazeutische zusammensetzung mit antikrebswirkung und methode fuer die behandlung von krebs.
JPS5786254A (en) Healthful food
Wenderoth Aspects of the new eicosanoid-research.).